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ABSTRACT 
 
Trends in Prediabetes and Associated Comorbid Conditions in Adolescents Aged 12 to 19 Years, Between 
2003 and 2014.   
 
By 
 
Taylor Patrice Dias 
 
04/16/2018 
 
 
 
NTRODUCTION:  Understanding of the trends in Pre-Diabetes (PD), a reversible condition and 
precursor/risk factor for Type II Diabetes Mellitus (T2DM), among adolescents may help to 
develop robust public health initiatives for slowing the epidemic of T2DM and its associated 
comorbidities. Currently, published research only investigates only the prevalence of T2DM and 
T1DM in the adolescent population with no focus on PD. We have  the following three 
hypotheses: the prevalence of PD will be increasing during the study period, the prevalence of 
both comorbid conditions will be increasing in prevalence, there association of PD with each of 
the comorbid conditions will grow stronger over the study period.  
 
AIM:  Our aim is to determine the prevalence of PD and associated comorbid conditions in the 
adolescent population. Slowing the progress of this epidemic is crucial for improving the long-
term quality of life for high-risk populations, and can prevent adolescents from having 
expensive chronic conditions as they progress to adulthood.  
 
 
METHODS:  Data from NHANES  2003  - 2014 was used conduct analyses. The study sample was 
restricted to include only participants aged 12 to 19 years, and participants who were selected 
for lab work as this is the smallest  subset of the participants for each year. Proper sample 
weights, according to sampling methodology were used, to obtain prevalence value for each 
year, as well as to obtain correlation values in SAS 9.4.  
 
RESULTS & Discussion:   Contrary to our hypotheses there was an observed decrease in 
prevalence of PD and LDL category as well as average LDL reading during the study period. 
Additionally, the associations of PD and the comorbid were weak, and showed no trend during 
the study period. However, the prevalence of overweightness/obesity remained constant 
during the study period, though the prevalence remained high.  
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Introduction  
 
 The prevalence of Type 2 Diabetes Mellitus (T2DM) has been rapidly increasing in the United 
States, and remains one of the top 10 causes of death in the United States. The American Diabetes 
Association (ADA) reported that there were 29.1 million cases of T2DM in 2015 in the American 
population.   There has also been a dramatic increase in the prevalence of T2DM among adolescents, with 
and observed increase of 7.1% annually from 2002 to 2012(Mayer-Davis et al., 2017).  As with most 
chronic diseases,  the observed  increase was the greatest in minority groups (i.e. Hispanics and African 
Americans) in the Unites States.   The CDC cites the report by Dr. Mayer-Davis and her colleagues noting 
that there is not much understood about the rise in incidence of T2DM, nor has an explanation for the 
variances among genders and racial-ethnic groups been identified.  It is crucial that we begin 
understanding the reasons for this growing epidemic, as the ADA currently reports it as the seventh 
leading cause of death in the United States.  Diabetes could continue to develop into a major public health 
crisis if there is not more investigation into the risk factors associated with the epidemic.   
There has been some research to investigate the clustering of metabolic syndromes across 
different racial ethnic groups. In 2014, Okosun,Annor, and colleagues found that the clustering of 
cardiometabolic risk factors is positively associated with elevated HbA1c. Okosun and his colleagues also 
noted that “the joint occurrence of abdominal obesity and high blood pressure were much more highly 
associated with elevated HbA1c “, lending more support to the concept that there needs to be more 
investigation into the comorbid conditions that are clustering together in the population. However, the 
target population of this research was not adolescents as will be in the present research, indicating there is 
a knowledge gap about the trends of metabolic conditions in adolescents in the American population.   
Several researchers have noted that there has been an epidemiologic shift in diabetes among the 
adolescent population, shifting from predominantly Type 1 Diabetes Mellitus (T1DM) to also including a 
high incidence of T2DM. Investigation into the origin or the epidemiologic shift have identified several 
behavioral changes that may have contributed to the shift in adolescents, including a more sedentary 
lifestyle and eating more calorie-dense, nutrient poor foods (Delahanty et al., 2013).  
The recent epidemiologic shift in diabetes in adolescents is concerning for several reasons. The 
first is that the prevalence of comorbid conditions, such as hypertension and arterial stiffness, is higher 
among children with T2DM than T1DM. It has been observed that adolescents with T2DM had a higher 
prevalence of most comorbid conditions, and were disproportionally effected with 72% having at least 
one complication or comorbidity (Dabelea et al., 2017).  Additionally,  there has been minimal 
investigation into the effects  that a longer burden of disease will have on the population. As more 
adolescents are being diagnosed with T2DM they will carry that burden into adulthood and throughout 
their lifetime.  A longer burden of diseases could lead to increased mortality and morbidity, and the 
medical and capital cost on society will increase dramatically (ADA).    
There’s a paucity of research examining biological precursors to the development of Diabetes, in 
an attempt to understand the current epidemic. For example, by understanding of the trends in Pre-
Diabetes (PD), a reversible condition and precursor/risk factor for T2DM, among adolescents may help to 
develop robust public health initiatives for slowing the epidemic of T2DM and its associated 
comorbidities. Currently, published research only investigates only the prevalence of T2DM and T1DM 
in the adolescent population with no focus on PD. Slowing the progress of this epidemic is crucial for 
improving the long-term quality of life for high-risk populations, and can prevent adolescents from 
having expensive chronic conditions as they progress to adulthood. There is currently a lack of research 
describing the trends of PD and associated comorbid conditions in adolescents, as the limited research 
available focuses on T2DM and T1DM.  The present study aims to analyze the trends of PD and a two of 
the associated comorbid conditions based on data from National Health and Nutrition Examination 
Survey (NHANES).  We have  the following three hypotheses: the prevalence of PD will be increasing 
during the study period, the prevalence of both comorbid conditions, cholesterol status and BMI category,  
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will be increasing in prevalence as well, and the association of PFG with each of the comorbid conditions 
will grow stronger over the study period. 
 
Methods  and Procedures  
 
2.1 Study Design  
 Data from the 2003 - 2014 NHANES (collected in two year increments) survey was used 
for analysis in the study.  Each survey is composed of a cross-sectional sample taken from the non-
institutionalized population in the United States, and is intended to be representative of the entire 
population.  The survey is composed of both a self-reported survey that is administered to participants, as 
well as a subsample of participants who are selected for physical and laboratory examination. NHANES 
uses a complex  sampling strategy ,which includes oversampling underrepresented populations to ensure 
that the sample is representative of the entire population.  A detailed description of the sampling 
methodology can be found on the National Center for Health Statistics website.   
2.2 Study Population 
 The study population was restricted to only include participants aged 12 to 19 years.  The 
minimum age of 12 years was selected because it is the minimum age for which laboratory and 
examination data were collected.  The dataset was further restricted in each year to only individuals who 
were selected for the laboratory examination. In the NAHNES sample for each year, a small subset was 
selected to go through a physical and laboratory examinations, in addition to the survey.  The subset that 
was selected for the laboratory examination represents the smallest sub-sample, of the sample for each 
year.  There were a total of 4,639 observations in the study, comprised of  varying  numbers of 
observations for each year.  
2.3 Definition of Terms  
 Ranges for all conditions were adapted from the ranges listed by the Mayo Clinic, as they 
continue to be a leader in the biological research community, and were assigned to each participant using 
the raw data, biomarker value. Both PD and T2DM were defined using the plasmas fasting glucose (PFG) 
(mg/dL) reading for each participant, ideal PFG was defined as being less than 100 mg/dL, PD as greater 
than or equal to 100 mg/dL and less than or equal to 125 mg/dL, and T2DM as a reading of greater than 
125 mg/dL.  A body mass index (BMI) category was also assigned to each participant based on his/her 
reading: a reading of lower than 18.5 kg/m2 was categorized underweight,  greater than or equal to 18.5 
kg/m2 and less than or equal to 24.9 was categorized ideal, greater than or equal to 25 kg/m2 and less than 
or equal to 29.9 kg/m2 was categorized overweight, and a reading of 130 kg/m2 or greater was categorized 
as obese. Additionally,  each participant was assigned a cholesterol category based on their low-density 
lipoprotein (LDL) reading in mg/dL: a reading of 129 mg/dL or less was categorized as ideal, a reading 
greater than or equal to 130 mg/dL and less than or greater than or equal to 159 mg/dL as borderline, and 
a reading greater than or equal to 160 mg/dL as high.   
2.4 Statistical Analysis  
 All analysis were completed using SAS 9.4 for windows.  In order to account for the 
complex sampling technique and to ensure that the results are applicable to the United States population 
as intended the proper weight, strata, and cluster variables were used. The weight assigned to the lab data 
was used as the weight for analysis, since it is the smallest subset of the study sample. Weighted 
frequencies were used to obtain prevalence values for each condition, during each study year.  Mean 
values for each biomarker were obtained using the variables LBXGLU (PFG), BXIBMI (BMI), and 
LBDLDL (LDL) for each participant each year. Additionally,  95% confidence intervals were obtained 
for the mean values for each biomarker at the beginning and end of the study to determine if the mean 
value has changed overtime. Pearson’s correlations were conducted to look at the associations of the 
biomarkers over the study period.  
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Results   
 
 The prevalence of PD was generally trending downwards during the study period. In 2004 the PD 
prevalence was 9.95% with a peak of 27.39% seen in 2008 (Figure 1), by 2014 prevalence had dropped to 
0% (according to the sample). Comparatively, the prevalence of adolescents having non-ideal LDL 
cholesterol levels remained relatively constant during the study period, though there was an overall 
decrease of 1.18%  during the study period (Figure 2).  The low prevalence each year was comprised 
mostly of adolescents who have a borderline LDL cholesterol level, and not those that are classified as 
high and very high. As seen in Figure 3, the prevalence of overweightness and obesity was trending 
upwards during the study period, with a peak prevalence in 2008 of 34.83% . It is also of note that the 
prevalence of obesity and overweightness as well as PD both peaked in 2008, as shown in figure 4 that 
combines the three previous figures to visualize how the three conditions trended simultaneously during 
the study period.  The trend in raw BMI reading is parallel to the trend in prevalence of overweightness 
and obesity.  Both were generally trending upwards, mean (95% CI)  BMI at the start of the study was 
23.74 kg/m2 (23.03, 24.47) and at the end of study the mean BMI had increased to 24.19 kg/m2 (23.24, 
25.13).  
Conversely to the accordance in trends between BMI category and mean BMI value, the trends in 
PD and LDL category display different trends that what was observed in the corresponding biomarker.  
Figures 5 displays the mean PFG value for the population during the study period, note that the trend in 
PFG differs from the trend in PD and is overall trending upwards. There was a sharp peak in 2008, 
followed by a steady increase the began in 2010.  In 2004 the mean (95% CI) PFG was 91.01 mg/dL 
(89.76, 92.25) and by the end of the study period it was 94.22 mg/dL (92.71, 95.74).In contrast to what 
was observed in medically defined cholesterol category, mean LDL values decreased in the populations 
after a peak in 2010(figure 6).  At the beginning of the study period the mean (95% CI)  LDL was 90.46 
mg/dL (88.34,92.58) and at the conclusion of the study period the mean value had dropped to 86.86 
mg/dL (83.22, 90.49).  Tables 1– 3 are frequency tables that give the frequency for each condition 
category (Diabetes, BMI, & Cholesterol), both weighted and unweighted frequencies are listed.   
There were no strong associations between PFG and either of the other two biomarkers (LDL and 
BMI) during the study period. In 2010 there was a statistically significant ( p<.0001) correlation between 
PFG and BMI the correlation coefficient remained near zero (r=.22) indicating a weak positive 
correlation. Correlation coefficients and p-values for each year are presented in Table 4.  
 
Discussion 
  
The purpose of this study was to determine the trends in PD in adolescents and determine if the 
trends are similar to the trends observed in T2DM. If more cases of PD can be identified in the population 
prevention efforts could be aimed at adolescent with PD who are likely at high-risk of developing T2DM.  
It is crucial to identify and treat adolescent before they develop T2DM, as once they have been diagnosed 
they cannot be cured. Again our three hypotheses were: the prevalence of PD will be increasing during 
the study period, the prevalence of both comorbid conditions, cholesterol status and BMI category,  will 
be increasing in prevalence as well, and the association of PFG with each of the comorbid conditions will 
grow stronger over the study period. 
The results of the study do not support our hypothesis that the prevalence of PD was increasing in 
the adolescent population between 2004-2014, in fact according to the NHANES data PD prevalence was 
trending downwards during this period. Though there was no increase in adolescents who would be 
clinically defined as having PD, the raw mean PFG values suggest that insulin resistance continued to 
increase in the population during the period, as indicated by upward shift of the 95% CI, with the only 
overlap observed at the upper confidence limit for 2004 and the lower confidence limit for 2014.  This 
finding could be indicative  of another possible peak in prevalence PD, similar to what was observed in  
the population in 2008, could occur again in the near future.  The mean PFG value in 2014 was only 6 
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points below being classified  clinically as PD, and it can be inferred that if PFG continues to trend 
upward the mean value could reach the clinical definition of PD in the coming years.  
 Our results also do not support the hypothesis that the prevalence of non-ideal cholesterol would 
be increasing during the study period. The prevalence of non-deal cholesterol remained low, and 
relatively constant with no significant variations during the study period. Upon reviewing the frequency 
table it  can be observed that most cases are classified as borderline versus high or very high, which 
indicates that most participants are still only at risk and do not yet have a cholesterol problem. This is a 
good sign for the adolescent population, and indicative that the consumption of foods high in saturated 
fatty acids may not yet begun to have a widespread effect on cardiovascular health in this population. 
Mean LDL level also remained constant as can be determined by the large overlap of the confidence 
intervals for 2004 and 2014.     
The prevalence of overweightness and obesity does not directly support hypothesis that 
conditions that are comorbid with PD was increasing in the adolescent population. However, the 
prevalence was high and relatively constant as the data indicates that approximately a third of the 
adolescent population was overweight or obese during the entire study period. This constant rate of 
obesity is  further supported by the mean BMI at the begging and the end of the study period, and the 
large overlap in the confidence intervals for both values.  Throughout the study period the mean BMI 
value remained near the threshold of overweight, and indicates that weight remains an issue in the 
adolescent population. Overweightness/obesity is a risk factor for T2DM and the high mean BMI values 
could be indicative that that the one of underlying problems that contributes to its diagnosis of PD still 
exists in the population at a high percentage.  As previously mentioned the mean PFG also experienced  a 
sharp peak in 2008,  which could indicates that until the obesity prevalence declines to a lower percentage 
of the population we cannot infer that the Diabetes epidemic is under control. Additionally, the high 
prevalence of obesity indicates  that the proposed causes of this  epidemic (sedentary life-style and 
consuming mostly calorie-dense, low nutrient foods) may still be an underlying issues within this age 
group. This indicates, in contrast to PD prevalence results, that public health interventions aimed at 
behavioral changes may need to be intensified to reach more adolescents, and more robustly evaluated for 
their efficacy.   
 Over all the results do not fully support our hypothesis, and are dissimilar from the trends seen in 
adults and the limited research available in the adolescent populations. Previous studies have identified 
that metabolic conditions cluster together and often excess weight is associated with poor cardiovascular 
health which was not observed in the present study.  Copeland et. al. outline several behavioral changes in 
the adolescent population, including eating consuming fast foods, snacking behaviors, and increased 
screen time, that are contributing to a “medical metamorphosis” in the populations. Their findings 
indicate that the T2DM is still a major concern among adolescents.  The amount of negative behavioral 
changes (sedentary lifestyle and poor diet)  and increasing prevalence of T2DM noted by the majority of 
research, though not supported by the findings of this research, indicates that the is a real public health 
crisis occurring in the United States adolescent population. T2D prevalence is rapidly increasing, and 
increased  7.1% annually over a time period that was almost concurrent with the present study period 
Mayer-Davis et al., 2017).  This indicats that there need to be more research into the prevalnce of PD, as 
adolescents must first have PD before T2DM. If we can identfity these adolescetns earlier, we may be 
able to implent more effective interventions and slow or stop the progressions of the disease.  
 
Limitations 
 
There are significant limitations to our analysis, which can provide an explanation for why the 
trends observed in the present research are dissimilar for the trends previously observed in the population.  
Though NHANES is intended to be representative of the populations our sample was so heavily restricted 
that it was no longer representative.  Additionally, the selected biomarkers may not have been sensitive 
enough as persons currently taking medications to control diabetes of cholesterol may have been included 
in the sample. Sample sizes varied each year, though weighted, and make it difficult to observe the trends. 
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Our results provide support for the funding of better surveillance of the adolescent population on a large 
scale similar to NHANES. These results demonstrate that it can be difficult to analyze trends in this 
population when there is not adequate surveillance data, or resources to complete data collection. Future 
research should aim to use a data source that only contains adolescents who are not being treated, and 
have not been diagnosed, or collect a new representative sample.  
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Appendix  
 
 
Figure 1:  Trend in prevalence pre-diabetes during the study period of 2004-2014. Prevalence 
was derived from the weighted frequencies of each year. The dashed line represents the linear 
trend during the time period.    
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Figure 2:  Trend in prevalence LDL levels that are above ideal (borderline, high and very high) 
during the study period of 2004-2014. Prevalence was derived from the combined weighted 
frequencies of each category, for each year. The dashed line represents the linear trend during the 
time period.    
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Figure 3:  Trend in prevalence of overweightness and obesity during the study period of 2004-
2014. Prevalence was derived from the combined weighted frequencies overweigh and obesity 
for each year. The dashed line represents the linear trend during the time period.    
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Figure 4: A trend comparison of the previous three figures to see how they vary overtime in 
relation to each other between 2004-2014.  Prevalence was derived from weighted frequencies 
for each variable for each year.   
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Figure 5:  Plasma glucose is biomarker used to determine diabetes status. The graph plots mean 
plasma glucose during the study period. The dashed line represents the trends over time in mean 
fasting plasma glucose value.   
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Figure 6: Low density lipoprotein (LDL) is biomarker that was used in this study to define 
cholesterol status. The graph plots mean LDL value during the study period.. The dashed line 
represents the trends over time in mean LDL value.   
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Figure 7: Body Mass Index (BMI) is used in this study to define overweightness and obesity. 
The graph plots mean BMI during the study period. The dashed line represents the trends over 
time in mean BMI value.   
 
 
Year Diabetes Category  Frequency 
Weighted 
Frequency 
Std Err of Wgt 
Freq 
2004 Normal 866 29,631,789 2,522,448 
 Pre-Diabetes  82 3,306,623 530,991 
 T2DM 4 187,921 118,195 
2006 Normal 718 27,227,634 2,302,560 
 Pre-Diabetes  164 6,158,284 898,100 
 T2DM 6 162,493 107,441 
2008 Normal 303 24,132,774 2,543,365 
 Pre-Diabetes  133 9,233,848 750,292 
 T2DM 5 341,628 162,568 
2010 Normal 465 28,453,483 2,250,846 
 Pre-Diabetes  96 4,656,405 618,390 
 T2DM 1 32,208 32,208 
2012 Normal 522 33,653,448 3,040,271 
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 Pre-Diabetes  2 55,920 42,599 
 T2DM 3 89,990 56,383 
2014 Normal 534 33,318,750 2,853,252 
 Pre-Diabetes  0 0 0 
 T2DM 3 215,480 178,321 
 
Table 1:  Frequency table illustrating the frequency each diabetes category during each year of 
the study period. Note that the weight frequencies were used to calculate prevalence values.   
 
 
 
Year BMI Category Frequency 
Weighted 
Frequency 
Std Err of Wgt 
Freq 
2004 Underweight  140 4,947,565 770,868 
 Normal  504 5,359,846 805,685 
 Overweight  159 17,400,743 1,809,421 
 Obese 143 5,239,162 455,178 
2006 Underweight  132 5,739,029 716,118 
 Normal  456 18,133,325 1,807,773 
 Overweight  156 4,963,645 400,476 
 Obese 140 4,637,681 870,118 
2008 Underweight  66 5,415,630 1,090,447 
 Normal  213 16,166,281 1,225,502 
 Overweight  100 7,254,304 1,378,743 
 Obese 59 4,279,515 1,093,389 
2010 Underweight  76 4,431,824 679,585 
 Normal  304 19,136,341 1,380,388 
 Overweight  97 5,200,511 570,381 
 Obese 80 4,143,178 635,772 
2012 Underweight  83 4,942,840 618,198 
 Normal  268 17,552,044 1,939,878 
 Overweight  103 6,465,762 969,480 
 Obese 73 4,838,712 785,880 
2014 Underweight  80 4,576,979 546,567 
 Normal  272 17,791,330 2,324,834 
 Overweight  91 5,660,084 932,642 
 Obese 94 5,505,838 860,496 
 
Table 2:  Frequency table illustrating the frequency each BMI category during each year of the 
study period. Note that the weight frequencies were used to calculate prevalence values.   
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Year 
Cholesterol 
Category Frequency  
Weighted 
Frequency 
Std Err of Wgt 
Freq 
2004 Ideal  883 30,755,962 2,375,018 
 Borderline  50 1,711,958 396,273 
 High  16 512,603 95,741 
 Very High  4 164,563 111,420 
2006 Ideal  820 31,423,209 2,458,918 
 Borderline  59 1,906,167 462,033 
 High  8 199,992 88,358 
 Very High  1 19,043 19,043 
2008 Ideal  412 31,321,697 2,244,972 
 Borderline  20 1,793,045 481,412 
 High  9 593,509 237,635 
 Very High  0 0 0 
2010 Ideal  520 30,591,295 2,208,417 
 Borderline  32 1,924,780 410,118 
 High  7 332,815 140,184 
 Very High  3 293,207 185,615 
2012 Ideal  489 31,557,413 2,868,239 
 Borderline  30 1,841,166 437,043 
 High  7 378,133 191,462 
 Very High  1 22,645 22,645 
2014 Ideal  512 31,511,235 2,588,281 
 Borderline  17 1,523,237 521,687 
 High  6 443,902 217,638 
 Very High  2 55,857 40,112 
 
Table 3:  Frequency table illustrating the frequency each cholesterol category during each year of 
the study period. Note that the weight frequencies were used to calculate prevalence values.   
 
 
 
 
Year LDL Correlation P-value BMI Correlation P-value2 
2004 0.001 0.957 0.110 0.0004 
2006 0.027 0.407 0.013 0.6890 
2008 0.026 0.571 -0.013 0.7850 
2010 0.022 0.600 0.217 <0.0001 
2012 0.092 0.032 0.083 0.0520 
2014 -0.022 0.598 0.077 0.0630 
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Table 4:  Correlation coefficients for each biomarker with PFG each year, and corresponding p-
values.   
